NXP900

News alerts, weekly reports and conference planners

Company:

Nuvectis Pharma

Drug class:

Src kinase inhibitor, YES1 inhibitor

Related drugs:

ARID1A mutation	Ovarian Cancer	ARID1A mutation	Ovarian Cancer	NXP900 Sensitive: B - Late Trials NXP900 Sensitive : B	NXP900 Sensitive: B - Late Trials NXP900 Sensitive : B
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	NXP900 Resistant: D – Preclinical NXP900 Resistant : D	NXP900 Resistant: D – Preclinical NXP900 Resistant : D
YES1 amplification	Esophageal Squamous Cell Carcinoma	YES1 amplification	Esophageal Squamous Cell Carcinoma	NXP900 Sensitive: D – Preclinical NXP900 Sensitive : D	NXP900 Sensitive: D – Preclinical NXP900 Sensitive : D

Associations
(3)